Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery

Human Molecular Genetics
Monica CardoneMaria Pia Cosma

Abstract

Mucopolysaccharidosis type II (MPSII; Hunter syndrome) is a lysosomal storage disorder caused by a deficiency in the enzyme iduronate 2-sulfatase (IDS). At present, the therapeutic approaches for MPSII are enzyme replacement therapy and bone marrow transplantation, although these therapies have some limitations. The availability of new AAV serotypes that display tissue-specific tropism and promote sustained expression of transgenes offers the possibility of AAV-mediated gene therapy for the systemic treatment of lysosomal diseases, including MPSII. We have characterized in detail the phenotype of IDS-deficient mice, a model of human MPSII. These mice display a progressive accumulation of glycosaminoglycans (GAGs) in many organs and excessive excretion of these compounds in their urine. Furthermore, they develop skeleton deformities, particularly of the craniofacial bones, and alopecia, they perform poorly in open-field tests and they have a severely compromised walking pattern. In addition, they present neuropathological defects. We have designed an efficient gene therapy approach for the treatment of these MPSII mice. AAV2/8TBG-IDS viral particles were administrated intravenously to adult MPSII mice. The plasma and tissue IDS ...Continue Reading

References

Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·L WangI M Verma
Jun 1, 2000·Bone Marrow Transplantation·C Peters, W Krivit
Oct 24, 2000·Blood Cells, Molecules & Diseases·G AltarescuN W Barton
Jun 19, 2002·Seminars in Neonatology : SN·J E Wraith
Aug 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Guang-Ping GaoJames M Wilson
Jul 23, 2004·Human Molecular Genetics·Diego Prieto RocesKurt von Figura
Sep 1, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Thomas J SferraYan Hu
Sep 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Carole VoglerWilliam S Sly
Oct 13, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Guangping GaoJames M Wilson

❮ Previous
Next ❯

Citations

Sep 19, 2007·Journal of Inherited Metabolic Disease·A R GarciaJ Muenzer
Apr 16, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hua LiHildegund C J Ertl
Feb 18, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Carmine SpampanatoAndrea Ballabio
Oct 20, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Huimin HuAlessandra d'Azzo
Oct 24, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alessandra TessitoreAlberto Auricchio
Oct 3, 2012·Proceedings of the National Academy of Sciences of the United States of America·Ha T HuynhWilliam S Sly
Nov 9, 2011·Orphanet Journal of Rare Diseases·Maurizio ScarpaUNKNOWN Hunter Syndrome Europena Expert Council
Sep 30, 2010·Human Molecular Genetics·Vinicia Assunta PolitoMaria Pia Cosma
Feb 19, 2010·Cellular and Molecular Life Sciences : CMLS·M Buono, Maria Pia Cosma
Dec 17, 2014·Expert Opinion on Drug Delivery·Daniel A WolfWalter C Low
Aug 31, 2007·Expert Opinion on Biological Therapy·Katherine P Ponder, Mark E Haskins
Sep 19, 2009·Matrix Biology : Journal of the International Society for Matrix Biology·Enrico MoroFrancesco Argenton
Feb 10, 2007·Brain Research·Richard L SidmanLamya S Shihabuddin
Oct 27, 2006·Biochimica Et Biophysica Acta·Guy L OdomJeffrey S Chamberlain
Aug 15, 2009·American Journal of Human Genetics·Vinicia Assunta Polito, Maria Pia Cosma
Nov 24, 2017·Journal of Inherited Metabolic Disease·Jitka RybováRobert Dobrovolný
Mar 14, 2007·Current Opinion in Neurology·Monica Cardone
Apr 19, 2011·Nature Reviews. Genetics·Federico Mingozzi, Katherine A High
Jun 10, 2018·EMBO Molecular Medicine·Hélène Fe GleitzBrian W Bigger
Jan 13, 2016·World Journal of Gastroenterology : WJG·Yi-Gang WangYan-Fang Sun
Feb 20, 2020·International Journal of Molecular Sciences·Francesca D'AvanzoRosella Tomanin
May 18, 2017·International Journal of Molecular Sciences·Marika SalvalaioRosella Tomanin
Jan 1, 2007·Expert Review of Endocrinology & Metabolism·Kim L McBride
Oct 5, 2007·Human Molecular Genetics·Carmine SettembreAndrea Ballabio
Sep 15, 2018·International Journal of Molecular Sciences·Beatrice Xuan HoBoon Seng Soh
May 28, 2019·Genetics and Molecular Biology·Edina PolettoGuilherme Baldo
Oct 17, 2018·Pediatric Research·Carlos J Alméciga-DíazShunji Tomatsu
Apr 27, 2019·International Journal of Molecular Sciences·Laura RigonRosella Tomanin
Jan 9, 2007·The Biochemical Journal·Alessandro FraldiMaria Pia Cosma
Nov 20, 2018·Journal of Neurochemistry·Helen Parker, Brian W Bigger
Nov 22, 2017·Expert Opinion on Orphan Drugs·Molly StapletonShunji Tomatsu
May 1, 2020·Frontiers in Molecular Biosciences·Jacob M FavretDaesung Shin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.